NEW YORK, NY / ACCESS Newswire / February 23, 2025 / Bronstein, Gewirtz & Grossman, LLC, a nationally recognized law firm, ...
Novo Nordisk A/S’s weight-loss and diabetes drugs are no longer in short supply, US regulators said, a decision that’s ...
Novo Nordisk ( NVO 5.29%) stock ran up 3.5% through 10:05 a.m. ET Friday morning on some good news for it (and for Eli Lilly ...
The U.S. Food and Drug Administration said on Friday there was no longer a shortage of Novo Nordisk’s popular weight-loss and ...
Novo Nordisk ( NVO -1.22%) stock is in a funk. Shares of the GLP-1 diet drug manufacturer have been sliding all week long, ...
The FDA has declared an end to the shortage of Novo Nordisk’s blockbuster drug semaglutide, threatening the ability for ...
The FDA’s decision will threaten the ability of compounding pharmacies to make far cheaper, unbranded versions of the ...
Novo Nordisk only prices in management's latest year guidance and underestimates the full market potential. See why I rate ...
Novo Nordisk thrives despite competition and explore its breakthrough amycretin study. Read here to know why we rate NVO ...
Novo Nordisk called out suppliers of compounded weight loss drugs following Hims & Hers’ controversial Super Bowl ad.
Following the resolution of Eli Lilly’s tirzepatide shortage in October, the FDA has officially declared an end to the supply ...
Shares of obesity-drug maker Novo Nordisk rose Friday after the Food and Drug Administration declared that the company’s popular medications Ozempic and Wegovy were no longer in shortage. A shortage o ...